FDA sees biotech generics many years off

03/26/2007 | Forbes

Generic versions of biotech drugs may be many years off, FDA deputy commissioner Janet Woodcock told a congressional panel. She said it could be a decade or more before the FDA has the science needed to safely approve biotech generics in the way copies of traditional drugs now are evaluated. The situation could be a plus for biotech firms that never have faced competition from generic versions of their drugs.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC